EUCTR2014-002673-11-Outside-EU/EEA进行中（未招募）1 期
A Phase 2/3, Open-Label Study to Evaluate the Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Virologically Suppressed Adolescents
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Currently on a stable antiretroviral regimen for = 6 consecutive months
- •12 years to < 18 years of age
- •Weight = 35kg (77 lbs.)
- •Subjects able to give written assent prior to any screening evaluations
- •Parent or guardian able to give written informed consent prior to any screening evaluations and willing to comply with study requirements
- •Plasma HIV-1 RNA levels < 50 copies/mL for = 6 months preceding the screening visit (measured at least twice using the same assay) and not experienced two consecutive HIV-1 RNA above detectable levels after achieving a confirmed (two consecutive) HIV-1 RNA below detectable levels on the current regimen in the past year.
- •CD4+ cell count > 100 cells/µL
- •No documented history of resistance to EVG, FTC, 3TC or TFV including, but not limited to, the presence of reverse transcriptase mutations K65R, K70E, M184V/I, or 3 or more thymidine analog-associated mutations (TAMs) that include M41L or L210W (TAMs are M41L, D67N, K70R, L210W, T215Y/F, K219Q/E/N/R).
- •Adequate renal function: Estimated glomerular filtration rate = 90 mL/min/1.73 m2
- •Clinically normal ECG (or if abnormal, determined by the investigator to be not clinically significant)
- •Hepatic transaminases (AST and ALT) = 5 x upper limit of normal (ULN)
- •No evidence of current HBV infection
- •No evidence of current HCV infection
- •For subjects on all agents except ATV, total bilirubin or normal direct bilirubin = 1.5 mg/dL
- •For all subjects on ATV, total bilirubin or normal direct bilirubin = 3.0 mg/dL
- •Adequate hematologic function (absolute neutrophil count = 500/mm3; platelets = 50,000/mm3; hemoglobin = 8.5 g/dL)
- •Negative serum pregnancy test for all female subjects
- •Females of childbearing potential (as defined in Appendix 5) must agree to utilize highly effective contraception methods or be non-heterosexually active or practice sexual abstinence from Screening throughout the duration of study treatment and for 30 days following discontinuation of investigational medicinal product.
- •Female subjects who utilize hormonal contraceptive as one of their birth control methods must have used the same method for at least three months prior to study dosing.
- •Male subjects must agree to utilize highly effective contraception methods during heterosexual intercourse or be non-heterosexually active, or practice sexual abstinence from Baseline throughout the study period and for 30 days following discontinuation of investigational medicinal product.
- •Male subjects must refrain from sperm donation from Day -1 through completion of the study and continuing for at least 30 days from the date of last dose of study drug.
- •Able to swallow oral tablets
- •Must be willing and able to comply with all study requirements
- •Life expectancy > 1 year
- •Lactating females must agree to discontinue nursing before initiating study drug
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 50
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A new AIDS-defining condition diagnosed within the 30 days prior to Screening
- •Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months of screening
- •Anticipated to require rifamycin treatment for mycobacterial infection while participating in the study. Note: prophylactic INH therapy for latent TB treatment is allowed.
- •Subjects experiencing decompensated cirrhosis (e.g., ascites, encephalopathy, etc.)
- •Pregnant or lactating subjects
- •Have an implanted defibrillator or pacemaker
- •Have any serious or active medical or psychiatric illness which, in the opinion of the Investigator, would interfere with subject treatment, assessment, or compliance with the protocol.
- •Current alcohol or substance abuse judged by the Investigator to potentially interfere with subject compliance.
- •Have history of significant drug sensitivity or drug allergy.
- •Known hypersensitivity to the study drugs, the metabolites or formulation excipients
- •Have been treated with immunosuppressant therapies or chemotherapeutic agents within 3 months of study Screening or expected to receive these agents during the study
- •A history of malignancy within the past 5 years (prior to Screening) or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma. Subjects with cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of Baseline and must not be anticipated to require systemic therapy during the study.
- •Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Baseline.
- •Have previously participated in an investigational trial involving administration of any investigational agent within 30 days prior to the study dosing.
- •Participation in any other clinical trial (including observational trials) without prior approval from sponsor is prohibited while participating in this trial.
- •Subjects receiving ongoing therapy with any of the medications specified in protocol section 4.3, including drugs not to be used with EVG, COBI, FTC, TDF and TAF
研究者
相似试验
进行中（未招募）
1 期
A Phase 1 clinical trial to test the safety, preliminary effects of increasing doses of AZD7648 alone and in combination with other anti-cancer agents in patients with advanced cancers..Advanced MalignanciesMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003688-73-GBAstraZeneca AB230
进行中（未招募）
1 期
A Phase IIa, Open Label Study to Evaluate the Safety of Afamelanotide in Patients with Early Parkinson's DiseaseMedDRA version: 20.0Level: SOCClassification code: 10029205Term: Nervous system disorders Class: 8MedDRA version: 21.1Level: LLTClassification code: 10013113Term: Disease Parkinson's Class: 10029205MedDRA version: 20.0Level: HLTClassification code: 10034005Term: Parkinson's disease and parkinsonism Class: 10029205MedDRA version: 20.0Level: PTClassification code: 10061536Term: Parkinson's disease Class: 100000004852Parkinson's DiseaseCTIS2022-502207-30-00Clinuvel Europe Limited10
进行中（未招募）
1 期
A Phase I/II Open-Label Study to Evaluate the Safety, Tolerability and Recommended Phase II Dose (RP2D) of GLG-801 in patients with Advanced Solid Tumors (Phase I); and safety, tolerability and anticancer activity of GLG-801 in patients with Metastatic TNBC (Phase II).EUCTR2017-005057-36-PLGLG Pharma S.A.80
进行中（未招募）
1 期
Evaluating the Safety and Efficacy of Full-Spectrum Medicinal Cannabis (FEN164) in Children with ASD.Mental Health - Autistic spectrum disordersAutism Spectrum DisorderACTRN12621000760875Fenix Innovation Group18
进行中（未招募）
1 期
Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients who are Anti-PD-1 or Anti-PD-L1 Treatment Naïvep53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC)MedDRA version: 21.1Level: LLTClassification code 10064025Term: Merkel cell carcinomaSystem Organ Class: 100000004864EUCTR2020-002820-35-NLKartos Therapeutics, Inc.175